Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $8.7100 (-6.44%) ($8.5400 - $9.3300) on Tue. Sep. 22, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.67% (three month average) | RSI | 55 | Latest Price | $8.7100(-6.44%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -2.6% a day on average for past five trading days. | Weekly Trend | ADAP advances 11.3% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) XLRE(28%) DRIV(23%) IWC(23%) IWM(23%) IWN(23%) | Factors Impacting ADAP price | ADAP will decline at least -2.335% in a week (0% probabilities). TLT(-13%) TIP(-13%) BNDX(-13%) BND(-11%) IPO(-9%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.335% (StdDev 4.67%) | Hourly BBV | 0 () | Intraday Trend | -6.6% | | | |
|
Resistance Level | $8.83 | 5 Day Moving Average | $10(-12.9%) | 10 Day Moving Average | $9.39(-7.24%) | 20 Day Moving Average | $8.83(-1.36%) | To recent high | -19.2% | To recent low | 11.4% | Market Cap | $1.347b | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |